|Bid||17.20 x 200|
|Ask||17.21 x 1000|
|Day's Range||17.10 - 17.23|
|52 Week Range||16.81 - 53.96|
|PE Ratio (TTM)||220.64|
|Dividend & Yield||1.10 (6.32%)|
|1y Target Est||N/A|
The biopharma successfully staved off a generic challenger for its most important drug.
Don’t buy the pain meds Citi is prescribing in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). In our view, it’s too late to fill that order and this is a better occasion to take on a pick-me-up, contrarian position in TEVA with a bullish short-term options play. Apologies are a rare bird with analysts on Wall Street, and for that I almost want to tip the hat for Citi’s actions in TEVA stock.
Shares of Valeant Pharmaceuticals International (VRX) have tumbled 14% in August as concerns about generic drugs following Teva Pharmaceutical Industries' (TEVA) earnings sparked a specialty-pharmaceutical stock selloff. Valeant, however, is trying to make back some of those losses this week, with the stock up more than 2% today after the company announced that it was close to fixing problems at a Bausch & Lomb plant. While this might seem like a minor piece of news, it has big implications for Valeant's stock.